JPH04346917A - Medicated cream and production thereof - Google Patents
Medicated cream and production thereofInfo
- Publication number
- JPH04346917A JPH04346917A JP3151176A JP15117691A JPH04346917A JP H04346917 A JPH04346917 A JP H04346917A JP 3151176 A JP3151176 A JP 3151176A JP 15117691 A JP15117691 A JP 15117691A JP H04346917 A JPH04346917 A JP H04346917A
- Authority
- JP
- Japan
- Prior art keywords
- extract
- scutellariae
- medicated cream
- effect
- added
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000006071 cream Substances 0.000 title claims abstract description 17
- 238000004519 manufacturing process Methods 0.000 title claims description 4
- 239000000284 extract Substances 0.000 claims abstract description 39
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims abstract description 13
- 239000008213 purified water Substances 0.000 claims abstract description 9
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 238000010438 heat treatment Methods 0.000 claims abstract description 4
- 238000003756 stirring Methods 0.000 claims abstract description 4
- 229940069445 licorice extract Drugs 0.000 claims description 9
- 229940057995 liquid paraffin Drugs 0.000 claims description 6
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- 238000001816 cooling Methods 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000002335 preservative effect Effects 0.000 claims description 5
- 239000002253 acid Substances 0.000 claims description 4
- 239000004264 Petrolatum Substances 0.000 claims description 3
- 235000019271 petrolatum Nutrition 0.000 claims description 3
- 229940066842 petrolatum Drugs 0.000 claims description 3
- 239000000463 material Substances 0.000 claims description 2
- 241000228212 Aspergillus Species 0.000 claims 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract description 16
- 206010020751 Hypersensitivity Diseases 0.000 abstract description 6
- 229960004949 glycyrrhizic acid Drugs 0.000 abstract description 6
- 235000019410 glycyrrhizin Nutrition 0.000 abstract description 6
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 abstract description 6
- 206010012442 Dermatitis contact Diseases 0.000 abstract description 4
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 abstract description 4
- 208000010247 contact dermatitis Diseases 0.000 abstract description 4
- LPLVUJXQOOQHMX-UHFFFAOYSA-N glycyrrhetinic acid glycoside Natural products C1CC(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2=O)C(O)=O)C)(C)CC2)(C)C2C(C)(C)C1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O LPLVUJXQOOQHMX-UHFFFAOYSA-N 0.000 abstract description 4
- UYRUBYNTXSDKQT-UHFFFAOYSA-N glycyrrhizic acid Natural products CC1(C)C(CCC2(C)C1CCC3(C)C2C(=O)C=C4C5CC(C)(CCC5(C)CCC34C)C(=O)O)OC6OC(C(O)C(O)C6OC7OC(O)C(O)C(O)C7C(=O)O)C(=O)O UYRUBYNTXSDKQT-UHFFFAOYSA-N 0.000 abstract description 4
- 229940099259 vaseline Drugs 0.000 abstract description 4
- 244000303040 Glycyrrhiza glabra Species 0.000 abstract description 3
- 230000007815 allergy Effects 0.000 abstract description 3
- 239000002537 cosmetic Substances 0.000 abstract description 3
- 239000004615 ingredient Substances 0.000 abstract description 3
- 229910052751 metal Inorganic materials 0.000 abstract description 2
- 239000002184 metal Substances 0.000 abstract description 2
- VTAJIXDZFCRWBR-UHFFFAOYSA-N Licoricesaponin B2 Natural products C1C(C2C(C3(CCC4(C)CCC(C)(CC4C3=CC2)C(O)=O)C)(C)CC2)(C)C2C(C)(C)CC1OC1OC(C(O)=O)C(O)C(O)C1OC1OC(C(O)=O)C(O)C(O)C1O VTAJIXDZFCRWBR-UHFFFAOYSA-N 0.000 abstract 2
- 241000246044 Sophora flavescens Species 0.000 abstract 2
- 239000001685 glycyrrhizic acid Substances 0.000 abstract 2
- 208000026935 allergic disease Diseases 0.000 abstract 1
- 230000002421 anti-septic effect Effects 0.000 abstract 1
- 230000001747 exhibiting effect Effects 0.000 abstract 1
- 239000012530 fluid Substances 0.000 abstract 1
- 239000004922 lacquer Substances 0.000 abstract 1
- 239000012188 paraffin wax Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 description 15
- 230000003110 anti-inflammatory effect Effects 0.000 description 10
- 230000000844 anti-bacterial effect Effects 0.000 description 9
- -1 triterpenoid glycosides Chemical class 0.000 description 9
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 8
- QISXPYZVZJBNDM-UHFFFAOYSA-N berberine Natural products COc1ccc2C=C3N(Cc2c1OC)C=Cc4cc5OCOc5cc34 QISXPYZVZJBNDM-UHFFFAOYSA-N 0.000 description 8
- YBHILYKTIRIUTE-UHFFFAOYSA-N berberine Chemical compound C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 YBHILYKTIRIUTE-UHFFFAOYSA-N 0.000 description 8
- 229940093265 berberine Drugs 0.000 description 8
- 238000006243 chemical reaction Methods 0.000 description 8
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 7
- 241000207929 Scutellaria Species 0.000 description 7
- 230000003266 anti-allergic effect Effects 0.000 description 7
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 6
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 5
- 229930013930 alkaloid Natural products 0.000 description 5
- 229930003935 flavonoid Natural products 0.000 description 5
- 150000002215 flavonoids Chemical class 0.000 description 5
- 235000017173 flavonoids Nutrition 0.000 description 5
- 229960000984 tocofersolan Drugs 0.000 description 5
- FXNFHKRTJBSTCS-UHFFFAOYSA-N Baicalein Natural products C=1C(=O)C=2C(O)=C(O)C(O)=CC=2OC=1C1=CC=CC=C1 FXNFHKRTJBSTCS-UHFFFAOYSA-N 0.000 description 4
- BIVBRWYINDPWKA-VLQRKCJKSA-L Glycyrrhizinate dipotassium Chemical compound [K+].[K+].O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@H]1CC[C@]2(C)[C@H]3C(=O)C=C4[C@@H]5C[C@](C)(CC[C@@]5(CC[C@@]4(C)[C@]3(C)CC[C@H]2C1(C)C)C)C(O)=O)C([O-])=O)[C@@H]1O[C@H](C([O-])=O)[C@@H](O)[C@H](O)[C@H]1O BIVBRWYINDPWKA-VLQRKCJKSA-L 0.000 description 4
- ZSBXGIUJOOQZMP-JLNYLFASSA-N Matrine Chemical compound C1CC[C@H]2CN3C(=O)CCC[C@@H]3[C@@H]3[C@H]2N1CCC3 ZSBXGIUJOOQZMP-JLNYLFASSA-N 0.000 description 4
- 229940087168 alpha tocopherol Drugs 0.000 description 4
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 4
- 229940101029 dipotassium glycyrrhizinate Drugs 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 229940075507 glyceryl monostearate Drugs 0.000 description 4
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 4
- 239000002076 α-tocopherol Substances 0.000 description 4
- 206010003645 Atopy Diseases 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- 201000004624 Dermatitis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- ZSBXGIUJOOQZMP-UHFFFAOYSA-N Isomatrine Natural products C1CCC2CN3C(=O)CCCC3C3C2N1CCC3 ZSBXGIUJOOQZMP-UHFFFAOYSA-N 0.000 description 3
- IPQKDIRUZHOIOM-UHFFFAOYSA-N Oroxin A Natural products OC1C(O)C(O)C(CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IPQKDIRUZHOIOM-UHFFFAOYSA-N 0.000 description 3
- 208000003251 Pruritus Diseases 0.000 description 3
- 208000030961 allergic reaction Diseases 0.000 description 3
- UDFLTIRFTXWNJO-UHFFFAOYSA-N baicalein Chemical compound O1C2=CC(=O)C(O)=C(O)C2=C(O)C=C1C1=CC=CC=C1 UDFLTIRFTXWNJO-UHFFFAOYSA-N 0.000 description 3
- 229940015301 baicalein Drugs 0.000 description 3
- IKIIZLYTISPENI-ZFORQUDYSA-N baicalin Chemical compound O1[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 IKIIZLYTISPENI-ZFORQUDYSA-N 0.000 description 3
- 229960003321 baicalin Drugs 0.000 description 3
- AQHDANHUMGXSJZ-UHFFFAOYSA-N baicalin Natural products OC1C(O)C(C(O)CO)OC1OC(C(=C1O)O)=CC2=C1C(=O)C=C(C=1C=CC=CC=1)O2 AQHDANHUMGXSJZ-UHFFFAOYSA-N 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 229960000735 docosanol Drugs 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 230000035876 healing Effects 0.000 description 3
- 241000411851 herbal medicine Species 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 230000007721 medicinal effect Effects 0.000 description 3
- 230000001737 promoting effect Effects 0.000 description 3
- 208000017520 skin disease Diseases 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 230000029663 wound healing Effects 0.000 description 3
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 3
- 229940058015 1,3-butylene glycol Drugs 0.000 description 2
- 241000894006 Bacteria Species 0.000 description 2
- VKJGBAJNNALVAV-UHFFFAOYSA-M Berberine chloride (TN) Chemical compound [Cl-].C1=C2CC[N+]3=CC4=C(OC)C(OC)=CC=C4C=C3C2=CC2=C1OCO2 VKJGBAJNNALVAV-UHFFFAOYSA-M 0.000 description 2
- RZZPDXZPRHQOCG-OJAKKHQRSA-O CDP-choline(1+) Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OCC[N+](C)(C)C)O[C@H]1N1C(=O)N=C(N)C=C1 RZZPDXZPRHQOCG-OJAKKHQRSA-O 0.000 description 2
- 206010012438 Dermatitis atopic Diseases 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 235000001453 Glycyrrhiza echinata Nutrition 0.000 description 2
- 235000017382 Glycyrrhiza lepidota Nutrition 0.000 description 2
- 239000004378 Glycyrrhizin Substances 0.000 description 2
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 2
- GUGOEEXESWIERI-UHFFFAOYSA-N Terfenadine Chemical compound C1=CC(C(C)(C)C)=CC=C1C(O)CCCN1CCC(C(O)(C=2C=CC=CC=2)C=2C=CC=CC=2)CC1 GUGOEEXESWIERI-UHFFFAOYSA-N 0.000 description 2
- HIMJIPRMECETLJ-UHFFFAOYSA-N Wogonin Natural products COc1cc(O)c(O)c2C(=O)C=C(Oc12)c3ccccc3 HIMJIPRMECETLJ-UHFFFAOYSA-N 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 230000001387 anti-histamine Effects 0.000 description 2
- 230000001139 anti-pruritic effect Effects 0.000 description 2
- 239000000739 antihistaminic agent Substances 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 230000003078 antioxidant effect Effects 0.000 description 2
- 235000006708 antioxidants Nutrition 0.000 description 2
- 201000008937 atopic dermatitis Diseases 0.000 description 2
- 235000019437 butane-1,3-diol Nutrition 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- VLARUOGDXDTHEH-UHFFFAOYSA-L disodium cromoglycate Chemical compound [Na+].[Na+].O1C(C([O-])=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C([O-])=O)O2 VLARUOGDXDTHEH-UHFFFAOYSA-L 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 238000005469 granulation Methods 0.000 description 2
- 230000003179 granulation Effects 0.000 description 2
- IPCSVZSSVZVIGE-UHFFFAOYSA-N hexadecanoic acid Chemical compound CCCCCCCCCCCCCCCC(O)=O IPCSVZSSVZVIGE-UHFFFAOYSA-N 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 229940010454 licorice Drugs 0.000 description 2
- 229930014456 matrine Natural products 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 230000000144 pharmacologic effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- XLTFNNCXVBYBSX-UHFFFAOYSA-N wogonin Chemical compound COC1=C(O)C=C(O)C(C(C=2)=O)=C1OC=2C1=CC=CC=C1 XLTFNNCXVBYBSX-UHFFFAOYSA-N 0.000 description 2
- INLFWQCRAJUDCR-IQVMEADQSA-N (1R,2S,4S,5'S,6R,7S,8R,9S,12S,13S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icosane-6,2'-oxane] Chemical compound O([C@@H]1[C@@H]([C@]2(CC[C@@H]3[C@@]4(C)CCCCC4CC[C@H]3[C@@H]2C1)C)[C@@H]1C)[C@]11CC[C@H](C)CO1 INLFWQCRAJUDCR-IQVMEADQSA-N 0.000 description 1
- OYHQOLUKZRVURQ-NTGFUMLPSA-N (9Z,12Z)-9,10,12,13-tetratritiooctadeca-9,12-dienoic acid Chemical compound C(CCCCCCC\C(=C(/C\C(=C(/CCCCC)\[3H])\[3H])\[3H])\[3H])(=O)O OYHQOLUKZRVURQ-NTGFUMLPSA-N 0.000 description 1
- MTJGVAJYTOXFJH-UHFFFAOYSA-N 3-aminonaphthalene-1,5-disulfonic acid Chemical compound C1=CC=C(S(O)(=O)=O)C2=CC(N)=CC(S(O)(=O)=O)=C21 MTJGVAJYTOXFJH-UHFFFAOYSA-N 0.000 description 1
- JCLFHZLOKITRCE-UHFFFAOYSA-N 4-pentoxyphenol Chemical compound CCCCCOC1=CC=C(O)C=C1 JCLFHZLOKITRCE-UHFFFAOYSA-N 0.000 description 1
- 241000497851 Anaphes Species 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000221377 Auricularia Species 0.000 description 1
- 241000700198 Cavia Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 239000011627 DL-alpha-tocopherol Substances 0.000 description 1
- 229930183217 Genin Natural products 0.000 description 1
- 241000202807 Glycyrrhiza Species 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- SKCKOFZKJLZSFA-UHFFFAOYSA-N L-Gulomethylit Natural products CC(O)C(O)C(O)C(O)CO SKCKOFZKJLZSFA-UHFFFAOYSA-N 0.000 description 1
- 206010027627 Miliaria Diseases 0.000 description 1
- 206010067572 Oestrogenic effect Diseases 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 235000021314 Palmitic acid Nutrition 0.000 description 1
- 208000008469 Peptic Ulcer Diseases 0.000 description 1
- 208000004880 Polyuria Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 240000003152 Rhus chinensis Species 0.000 description 1
- 235000014220 Rhus chinensis Nutrition 0.000 description 1
- 235000004443 Ricinus communis Nutrition 0.000 description 1
- 241000293871 Salmonella enterica subsp. enterica serovar Typhi Species 0.000 description 1
- 241000607768 Shigella Species 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- 241000219784 Sophora Species 0.000 description 1
- 241000295644 Staphylococcaceae Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 206010052428 Wound Diseases 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 230000000954 anitussive effect Effects 0.000 description 1
- 230000002467 anti-pepsin effect Effects 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 208000010668 atopic eczema Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000991 chicken egg Anatomy 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- IMZMKUWMOSJXDT-UHFFFAOYSA-N cromoglycic acid Chemical compound O1C(C(O)=O)=CC(=O)C2=C1C=CC=C2OCC(O)COC1=CC=CC2=C1C(=O)C=C(C(O)=O)O2 IMZMKUWMOSJXDT-UHFFFAOYSA-N 0.000 description 1
- 239000000287 crude extract Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 239000000645 desinfectant Substances 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- KCIDZIIHRGYJAE-YGFYJFDDSA-L dipotassium;[(2r,3r,4s,5r,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] phosphate Chemical compound [K+].[K+].OC[C@H]1O[C@H](OP([O-])([O-])=O)[C@H](O)[C@@H](O)[C@H]1O KCIDZIIHRGYJAE-YGFYJFDDSA-L 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 230000001076 estrogenic effect Effects 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 208000030533 eye disease Diseases 0.000 description 1
- 229930003944 flavone Natural products 0.000 description 1
- 150000002213 flavones Chemical class 0.000 description 1
- 235000011949 flavones Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004392 genitalia Anatomy 0.000 description 1
- 229930182470 glycoside Natural products 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229940074774 glycyrrhizinate Drugs 0.000 description 1
- 230000002949 hemolytic effect Effects 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 210000003405 ileum Anatomy 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000002075 main ingredient Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- 239000000401 methanolic extract Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- WQEPLUUGTLDZJY-UHFFFAOYSA-N n-Pentadecanoic acid Natural products CCCCCCCCCCCCCCC(O)=O WQEPLUUGTLDZJY-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 208000011906 peptic ulcer disease Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 230000001568 sexual effect Effects 0.000 description 1
- 239000002453 shampoo Substances 0.000 description 1
- 239000002884 skin cream Substances 0.000 description 1
- 206010040872 skin infection Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 239000003270 steroid hormone Substances 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- BWMISRWJRUSYEX-SZKNIZGXSA-N terbinafine hydrochloride Chemical compound Cl.C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 BWMISRWJRUSYEX-SZKNIZGXSA-N 0.000 description 1
- 201000004647 tinea pedis Diseases 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000000606 toothpaste Substances 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 231100000397 ulcer Toxicity 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 235000004835 α-tocopherol Nutrition 0.000 description 1
Landscapes
- Medicinal Preparation (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
Description
【0001】0001
【産業上の利用分野】本発明は薬用クリーム及び薬用ク
リームの製造法に関し、アレルギー、又特に金属、化粧
品、ウルシ等の接触性皮膚炎に有効な薬用クリームに関
するものである。BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to a medicated cream and a method for producing a medicated cream, and more particularly to a medicated cream that is effective against allergies, and particularly for contact dermatitis caused by metals, cosmetics, sumac, etc.
【0002】0002
【従来の技術】抗体が血清に認められず、細胞によって
仲介されるアレルギー反応をIV型のアレルギー反応と
呼ぶが、細菌、ウイルスカビ等の感染に伴う反応や、金
属、化粧品、ウルシ等の接触性皮膚炎などがこれに属す
る。[Prior Art] An allergic reaction in which antibodies are not detected in the serum and is mediated by cells is called a type IV allergic reaction. This includes sexual dermatitis.
【0003】然して細菌等の感染に伴う反応の場合には
細菌等の除去により対応策はあるが、アレルギー、接触
性皮膚炎には適当な対応治療法はステロイドホルモン以
外には提案されていない。[0003] In the case of a reaction associated with infection with bacteria, etc., countermeasures include removal of the bacteria, etc., but no appropriate treatment method other than steroid hormones has been proposed for allergies and contact dermatitis.
【0004】然して甘草根は古くから消炎効果がある薬
草として知られており、その有効成分であるグリチルリ
チン酸類は抗炎、抗アレルギー、抗消化性潰瘍作用など
のため、急性、慢性の皮膚炎の他、アフタ性口内炎など
に効果があるとして基礎化粧品や歯磨中に添加されてい
るものがある。Licorice root has long been known as a medicinal herb with anti-inflammatory effects, and its active ingredients, glycyrrhizinic acid, have anti-inflammatory, anti-allergic, and anti-peptic ulcer effects, so they can be used to treat acute and chronic dermatitis. In addition, some are added to basic cosmetics and toothpastes because they are said to be effective against aphthous stomatitis.
【0005】漢方におけるオウゴンの作用は「炎症を去
り、水毒を除き、清涼解熱と離尿の効がある」(新本草
備要)とされている。オウゴンの一般薬理作用について
は緩下作用、離尿作用があることは確認されている。
又、オウゴンの成分がフラボノイドであるところから所
謂ビタミンP様活性として抗炎症作用が調べられ、アス
ピリンに匹敵する効果が認められている。更に、オウゴ
ンの抗アレルギー作用について、感作したモルモットの
摘出回腸でSchultz−Dale反応をみると強い
抑制効果が認められる。[0005] In Chinese medicine, Scutellariae is said to have the effect of ``relieving inflammation, removing water poison, cooling, relieving fever, and urinating'' (Shinbonso Biyō). Regarding the general pharmacological effects of scutellariae, it has been confirmed that it has laxative and diuretic effects. Furthermore, since Scutellariae contains flavonoids, its anti-inflammatory effect has been investigated as a so-called vitamin P-like activity, and it has been found to have an effect comparable to that of aspirin. Furthermore, regarding the antiallergic effect of Scutellariae, a strong suppressive effect was observed when examining the Schultz-Dale reaction in the isolated ileum of sensitized guinea pigs.
【0006】オウバクは、オウレン、オウゴンと共にベ
ルベリンを主成分とする生薬であるが、漢方に於ける用
法はオウレン、オウゴンと異なる場合が多い。オウバク
については消化器作用、眼疾患など殺菌作用を推測させ
る用法が多い。又、オウバクの薬効には外用剤としての
用法に特徴があり、ベルベリンは外用殺菌剤として単な
る殺菌作用では説明出来ない創面治療促進作用があると
報告されている。[0006] Scutellariae is a herbal medicine containing berberine as a main component, along with Scutellaria scutellariae and Scutellariae scutellariae, but its usage in Chinese medicine is often different from that of Scutellaria scutellariae and Scutellariae. There are many uses for Aubaku that suggest bactericidal effects such as digestive effects and eye diseases. In addition, the medicinal efficacy of Auricularia spp. is characterized by its use as an external agent, and it has been reported that berberine, as an external disinfectant, has a wound healing promoting effect that cannot be explained by mere bactericidal action.
【0007】クララはmatrineを主アルカロイド
とするもので、湿疹、水虫などの皮膚疾患、口内炎等に
用いられる[0007] Clara has matrine as its main alkaloid and is used for skin diseases such as eczema and athlete's foot, stomatitis, etc.
【0008】[0008]
【発明が解決しようとする問題点】しかしこれらは従来
漢方薬として使用され、いわゆる煎じ薬として、又、軟
膏剤として使用されているが、その一般的薬理について
は殆ど実験段階であり、これらを組み合わせてその相乗
効果をもたらす使用方法は従来全く行われていなかった
。[Problems to be solved by the invention] However, these have been used as traditional Chinese herbal medicines, so-called decoctions, and ointments, but their general pharmacology is still at the experimental stage, and it is difficult to combine them. Conventionally, no method of use has been used to bring about this synergistic effect.
【0009】[0009]
【問題点を解決するための手段】そこで本発明に於いて
はオウバク、オウゴンは共にベルベリンを主成分とする
生薬であるが、夫々はベルベリンで代表される薬効と明
らかに相違するものがあり、又漢方における用法も様々
で異なることが多い点に着目し夫々の成分を有効に生か
し、更に皮膚障害治癒作用があり、抗アレルギー作用を
有するトリテルペノイト配糖体を6〜14%含有し、そ
の代表成分glycyrrhizinやglalric
acid,gabrolide等数多くのサポゲニン、
多数のフラボノイド、フラボン類を利用できる甘草を配
し、接触性皮膚炎に有効な薬用クリームに仕立てんとす
るもので、グルチルリチン酸を主体とする甘草抽出体を
0.05〜0.5%を含有させることを特徴とする薬用
クリーム請求項2,3と、基材のスクワラン、ワセリン
、流動パラフィンを加熱して混和溶解し、これに防腐剤
を含む熱精製水を加えて乳化し、これに甘草抽出体及び
オウゴン抽出液、オウバク抽出液、クララ抽出液を加え
た後、撹拌しながら冷却させることを特徴とする薬用ク
リームの製造方法を提案せんとするものである。[Means for solving the problem] Accordingly, in the present invention, Scutellariae and Scutellariae are both herbal medicines containing berberine as a main ingredient, but each has clearly different medicinal effects from the medicinal effects represented by berberine. In addition, we focused on the fact that there are many different uses in Chinese medicine, and made effective use of each ingredient.In addition, it contains 6 to 14% of triterpenoid glycosides, which have skin disorder healing effects and antiallergic effects. Ingredients glycyrrhizin and glarric
Many sapogenins such as acid and gabrolide,
This is a medicated cream that is effective for contact dermatitis, containing licorice that can utilize a large number of flavonoids and flavones, and contains 0.05 to 0.5% of licorice extract, which mainly contains glutyrrhizic acid. According to claims 2 and 3, the medicated cream is heated to mix and dissolve the base materials squalane, petrolatum, and liquid paraffin, and emulsify the mixture by adding hot purified water containing a preservative. The purpose of the present invention is to propose a method for producing a medicated cream, which is characterized by adding a licorice extract, a scutellariae extract, a scutellariae extract, and a clara extract, followed by cooling while stirring.
【0010】以下、実施例により本発明を詳細に説明す
る。先ず、乳化剤としてモノステアリン酸グリセリン、
ポリオキシエチレン硬化ヒマシ脂、防腐剤としてパラオ
キシ安息香酸ブチルを加熱して混和溶解する。これに防
腐剤パラオキシ安息香酸メチルを溶解した熱精製水を加
えて乳化する。これに甘草エキスであるが、glycy
rrhizinやそのゲニンのglycyrrheti
c acidは副腎皮質の水電解質や糖質ホルモン様
作用、エストロゲン作用、鎮咳作用、抗炎症作用、抗ア
レルギー作用など数多くの薬理効果があるが、これを主
剤として0.05〜0.5%まで含有させる。甘草には
多数のグリチルリチン酸があるが、グリチルリチン酸モ
ノアカモニウム及びカリウムは熱水には溶けるが、放冷
するとゲル状になり、冷水には溶けにくい。P−グリチ
ルリチン酸はピリジンに溶けやすく、水には殆ど溶けな
い等水に溶けないものが多い中でグリチルリチン酸ジカ
リウムは常温で水に85%溶解するので使用し易い。又
、酸化防止剤としてトコフェロール就中、酢酸−dl−
α−トコフェロールを適量加える。The present invention will be explained in detail below with reference to Examples. First, glyceryl monostearate as an emulsifier,
Polyoxyethylene hardened castor butter and butyl paraoxybenzoate as a preservative are mixed and dissolved by heating. Heat purified water in which the preservative methyl p-oxybenzoate is dissolved is added to this to emulsify. This is licorice extract, glycy
rrhizin and its genin glycyrrheti
C acid has many pharmacological effects such as water electrolyte and carbohydrate hormone-like effects on the adrenal cortex, estrogenic effects, antitussive effects, anti-inflammatory effects, and anti-allergic effects. Contain. Licorice contains a large number of glycyrrhizic acids, and monoachamonium and potassium glycyrrhizinate are soluble in hot water, but become gel-like when left to cool and are difficult to dissolve in cold water. P-glycyrrhizinic acid is easily soluble in pyridine, and there are many substances that are insoluble in water, such as hardly soluble in water, but dipotassium glycyrrhizinate is easy to use because it is 85% soluble in water at room temperature. In addition, as an antioxidant, tocopherol, acetic acid-dl-
Add an appropriate amount of α-tocopherol.
【0011】次にオウゴンは主成分のフラボノイドはb
aicalin4.3%、baicalein、wog
onin0.5%、wogonin glucuro
nide、orxylinA、この他ステロイド、糖類
が存在するオウゴンの抗アレルギー作用の有効成分はb
aicalinであり、そのgluconのbaica
leinはモル比でbaicalinと同程度のmed
iator有利抑制作用を示したので活性構造はbai
clein部分にある。baicleinはanaph
ylexis型反応を抑制するのみならず、reagi
nによって惹起されるアトピー型の反応をも抑制する。[0011] Next, the main component of flavonoids in Scutellariae is b.
aicalin4.3%, baicalin, wog
onin 0.5%, wogonin glucuro
The active ingredient of Scutellaria scutellariae's antiallergic effect, which contains nide, orxylin A, and other steroids and sugars, is b.
aicalin and its glucon baica
Lein has the same molar ratio as baicalin.
The active structure is bai because it showed an advantageous inhibitory effect on iator.
It's in the klein part. baiklein is anaph
In addition to suppressing ylexis-type reactions,
It also suppresses atopic reactions induced by n.
【0012】又、アトピー型抑制剤であるrisodi
um cromoglycate(DSCG)はba
icaleinと共通のchromono骨格を持つが
、DSCGはreaginによる反応しか押さえられな
いのに対しbaicaleinはnon−reagin
による反応をも押さえることが出来る。以上のことから
baicaleinがアレルギー反応の発現の機序のう
ち従来の薬物では及ばない作用点に作用することが解か
る。又、オウゴンは赤痢菌、チフス菌、緑膿菌、ブドウ
球菌、溶血性レンサ球菌等に対し、抗菌作用があるとす
る主張がある。[0012] Also, risodi, which is an atopic type inhibitor,
um chromoglycate (DSCG) is ba
Although it has the same chromono skeleton as icalein, DSCG can only suppress reactions by reagin, whereas baicalein can only suppress reactions by reagin.
It is also possible to suppress reactions caused by From the above, it is clear that baicalein acts on a point of action in the mechanism of allergic reaction that is not reached by conventional drugs. There is also a claim that Scutellariae has antibacterial effects against Shigella, Salmonella typhi, Pseudomonas aeruginosa, Staphylococcus, and hemolytic Streptococcus.
【0013】これらオウゴンは日局オウゴンのエタノー
ルによる抽出物を1.3−ブチレングリコールに溶解し
たものでbaicalin0.15〜0.25w/v%
含むが、これを全体の1〜10%加える。[0013] These Scutellariae are prepared by dissolving an ethanol extract of Japanese Scutellariae in 1,3-butylene glycol, and contain 0.15 to 0.25 w/v% of baicalin.
However, it should be added to 1 to 10% of the total amount.
【0014】オウバクは殺菌作用を有すること前述した
が、ブドウ球菌に対し5%で発育阻止作用を認められ、
肺炎菌には最も強い抗菌力を示し、ベルベリン0.62
5%、オウバク末は0.015%の濃度まで阻止作用を
示した。[0014] As mentioned above, Aubaku has a bactericidal effect, but it has also been found to inhibit the growth of staphylococci at 5%.
It shows the strongest antibacterial activity against Pneumococcus, with 0.62% of berberine
5%, and Aubacus powder showed an inhibitory effect up to a concentration of 0.015%.
【0015】又オウバクの薬効には単なる殺菌作用の強
さでは説明できない創面治癒作用があるが、例えばウサ
ギは背部皮膚に作成した筋肉に達した2cm2の新鮮創
傷の治癒はアクリノールに比べてベルベリン溶液処理群
が明らかに早かった。試験管での殺菌効力は明らかに合
成殺菌剤に比し弱いので、収斂性の抗炎症作用が治癒の
促進に関与しているものと思われる。又オウバクのアル
カロイド以外の成分としてリノール酸、パルミチン酸と
フィトステリンのエステルが同定されている。[0015] Also, the medicinal effect of Aurubaku has a wound-healing effect that cannot be explained simply by the strength of its bactericidal effect; for example, in rabbits, berberine solution was more effective in healing a fresh wound of 2 cm2 that reached the muscles created on the back skin than acrilinol. The treatment group was clearly faster. Since the bactericidal efficacy in vitro is clearly weaker than that of synthetic bactericides, it is likely that the astringent anti-inflammatory effect is involved in promoting healing. Furthermore, esters of linoleic acid, palmitic acid, and phytosterin have been identified as components other than alkaloids.
【0016】古来オウバク末は火傷、湯ただれに用いら
れ、近年では受精卵を用いた抗炎症作用のスクリーニン
グ研究に於いて強い抗炎症作用検出されている。即ち、
受精鶏卵の胚に検体を浸漬した濾紙のディスクを作用さ
せ肉芽形成を阻害する作用を指標として活性を調べたと
ころ、オウバクの50%メタノール抽出粗エキスは50
0μg/diseの用量で53%の肉芽阻止作用を示し
た。塩酸ベルベリンは50μg/diseの用量で68
.8%の抑制を示した。オウバクの炎症に関与する成分
は明確でない。日局オウバクの1.3ブチレングリコー
ル抽出液で、ベルベリンを塩化ベルベリンとして0.1
5〜0.25w/v%含むものを使用し、全体の1〜1
0%を含有させる。[0016] Since ancient times, the powder has been used for burns and hot water sores, and in recent years, a strong anti-inflammatory effect has been detected in screening studies using fertilized eggs. That is,
When we examined the activity using a filter paper disk soaked with the sample on the embryo of a fertilized chicken egg, using the effect of inhibiting granulation formation as an indicator, we found that the crude extract of 50% methanol extract of A.
At a dose of 0 μg/dise, it showed a granulation inhibition effect of 53%. Berberine hydrochloride at a dose of 50 μg/dise68
.. showed an inhibition of 8%. It is not clear which components are involved in inflammation in Aerialis. 1.3 butylene glycol extract of Japanese Pharmacopoeia oubaku, 0.1 berberine as berberine chloride
Use one containing 5 to 0.25 w/v%, and 1 to 1 of the total
Contains 0%.
【0017】クララはマメ化のsophora fl
avecens Aitonの根をそのまま50v/
v%エタノール溶液で抽出したものに1.3−ブチレン
グリコールと精製水の混液を加えたもので、アルカロイ
ドの主成分である(+)−matrine、副成分たる
(+)−oxynatrine等を含有し、又フラボノ
類としてXanthoumol、isoranthoh
amol等を含有する。これらは皮膚疾患、皮膚感染症
、あせも、ただれ、陰部掻痒症等に用いられる。又、蛇
床子と合わせると止痒効果が強まる。該クララ液を全体
の1〜10%を含有させる。[0017] Clara is a beanful sophora fl
Avecens Aiton root as it is 50v/
A mixture of 1,3-butylene glycol and purified water is added to the extract with v% ethanol solution, and it contains (+)-matrine, which is the main component of alkaloids, and (+)-oxynatrine, which is a subcomponent. , and flavonoids such as Xanthoumol and isorantho.
Contains amol etc. These are used for skin diseases, skin infections, heat rash, sores, genital pruritus, etc. Also, when combined with jaboko, the anti-pruritic effect is enhanced. The Clara liquid is contained in an amount of 1 to 10% of the total amount.
【0018】前述の乳化剤に甘草エキス就中グリリチル
酸ジカリウム、酸化防止剤の酢酸−dl−α−トコフェ
ロール及びオウゴン抽出液、オウバク抽出液、クララ抽
出液を各1〜10%加えた後、撹拌しながら冷却し、製
品を得る。To the above-mentioned emulsifier were added 1 to 10% each of licorice extract, dipotassium glyricylate, antioxidant -dl-α-tocopherol, and scutellariae extract, scutellariae extract, and clara extract, and then stirred. While cooling, obtain the product.
【0019】〔実用例1〕
グリチルリチン酸ジカリウム 0.
05%酢酸−d1−α−トコフェロール 0
.05%スクワラン
10.0%ワセリン
25.
0%流動パラフィン
15.0%ベヘニルアルコール
2.0%テトラオレイ
ン酸ポリオキシエチレンソルビット(60B.O)
2.0%
モノステアリン酸グリセリン
7.0%ポリオキシエチレン硬化ヒマシ油
5.0%パラオキシ安息香酸ブチル
適量オウゴン抽出液
1.0%精製
水
残[Practical Example 1] Dipotassium glycyrrhizinate 0.
05% acetic acid-d1-α-tocopherol 0
.. 05% squalane
10.0% Vaseline
25.
0% liquid paraffin
15.0% behenyl alcohol
2.0% polyoxyethylene sorbitol tetraoleate (60B.O)
2.0% Glyceryl monostearate
7.0% polyoxyethylene hydrogenated castor oil
5.0% Butyl paraoxybenzoate
Appropriate amount of Scutellariae extract
1.0% purified water
Residue
【0020】〔実用例2〕
グリチルリチン酸ジカリウム
0.3%酢酸−d1−α−トコフェロール
1.0%スクワラン
15.0%ワセリン
1
5.0%流動パラフィン
15.0%ベヘニルアルコール
5.0%テトラオ
レイン酸ポリオキシエチレンソルビット(60B.O)
2.0%
モノステアリン酸グリセリン
7.0%ポリオキシエチレン硬化ヒマシ油
5.0%パラオキシ安息香酸ブチル
適量オウゴン抽出液
1.0%オウ
バク抽出液
7.0%精製水
残上記
のクリームは抗アレルギー作用を有しながら、殺菌作用
が高まることが判明した。[Practical example 2] Dipotassium glycyrrhizinate
0.3% acetic acid-d1-α-tocopherol
1.0% squalane
15.0% Vaseline
1
5.0% liquid paraffin
15.0% behenyl alcohol
5.0% polyoxyethylene sorbitol tetraoleate (60B.O)
2.0% Glyceryl monostearate
7.0% polyoxyethylene hydrogenated castor oil
5.0% Butyl paraoxybenzoate
Appropriate amount of Scutellariae extract
1.0% Aurubax extract
7.0% purified water
It has been found that the above cream has an anti-allergic effect and has an enhanced bactericidal effect.
【0021】〔実用例3〕
グリチルリチン酸ジカリウム 0.
08%酢酸−d1−α−トコフェロール
%スクワラン
10.0%ワセリン
20.0%流動パラフィン
15.0%ベヘニルアルコール
2.0%テト
ラオレイン酸ポリオキシエチレンソルビット(60B.
O) 2.0%
モノステアリン酸グリセリン
6.0%ポリオキシエチレン硬化ヒマシ油
6.0%パラオキシ安息香酸ブチル
適量オウゴン抽出液
1.0%オウ
バク抽出液
1.0%クララ抽出液
10.0%パラオキシ安息
香酸メチル 適量
精製水
残上記のクリームは止痒
効果が優れていることが判明した。[Practical Example 3] Dipotassium glycyrrhizinate 0.
08% acetic acid-d1-α-tocopherol
% squalane
10.0% Vaseline
20.0% liquid paraffin
15.0% behenyl alcohol
2.0% polyoxyethylene sorbitol tetraoleate (60B.
O) 2.0% glyceryl monostearate
6.0% polyoxyethylene hydrogenated castor oil
6.0% Butyl paraoxybenzoate
Appropriate amount of Scutellariae extract
1.0% Aurubax extract
1.0% Clara extract
10.0% methyl paraoxybenzoate appropriate amount purified water
The above cream was found to have excellent antipruritic effects.
【0022】各実用例について洗髪シャンプー、リンス
等に毎日接触しており、且つ、皮膚に炎症のある美容師
多数人に使用して頂いた処、その炎症にもよるが、早い
人で数日、遅い人でも数週間以内にかゆみがとれ、炎症
が治った、又は軽くなった。各実用例間の差については
症例が少なく、判明するのに時間が必要である。[0022] Regarding each practical example, it was used by many hairdressers who come into contact with hair shampoos, conditioners, etc. every day and who also have skin irritation. Even in slow-acting patients, the itching subsides within a few weeks and the inflammation subsides or becomes less severe. There are few cases and it will take time to find out the differences between each practical example.
【0023】下記に実用例1の使用例の効果を示す。The effects of the usage example of Practical Example 1 are shown below.
【0024】下記に実用例2の使用例の効果を示す。The effects of the usage example of Practical Example 2 are shown below.
【0025】又、各実用例ともアトピー性皮膚炎に対し
有効性が高いことが判明した。アレゲルンは単一でなく
複合的なものであるため、複合的な本品によって対症効
果がでる。又、これら実用例に対し、マレイン酸クロフ
ェニラミンを抗ヒスタミンとして配合したが、かゆみの
刺激が中和されて有効であることが判かった。[0025] Furthermore, it was found that each practical example was highly effective against atopic dermatitis. Since Allegeln is not a single product but a compound, the compound product will have a symptomatic effect. Furthermore, for these practical examples, clopheniramine maleate was added as an antihistamine, which was found to be effective in neutralizing itching irritation.
【0026】実施例3によるアトピー性皮膚炎の汗疹性
苔癬化型に対する有効率を示す。下段は坑ヒスタミン配
合の使用例を示す。[0026] The effectiveness rate against the lichenified lichenoid type of atopic dermatitis according to Example 3 is shown. The lower row shows an example of the use of antihistamine formulations.
【0027】[0027]
【発明の効果】上記の如き本発明によれば、グルチルリ
チン酸を主体とする甘草抽出体を0.05〜0.5%、
オウゴン抽出液を1〜10%、オウバク抽出液を1〜1
0%、クララ抽出液を1〜10%を含有させた薬用クリ
ームを、基材のスクワラン、ワセリン、流動パラフィン
を加熱して混和溶解し、これに防腐剤を含む熱精製水を
加えて乳化し、これに甘草抽出体及びオウゴン抽出液、
オウバク抽出液、クララ抽出液を加えた後、撹拌しなが
ら冷却させて製造するようにしたので、甘草エキスの有
する抗炎症作用、オウゴン抽出液のフラボノイドとして
の抗炎症作用、抗アレルギー作用、アトピー型反応の抑
制作用、オウバク抽出液の有するベルベリン、アルカロ
イド等による収斂状の抗炎症作用を基とする創面治癒促
進作用、抗炎症作用、クララ抽出液の有する主アルカロ
イトのマトリンの潰瘍発生予防能力、皮膚感染症の対応
力等の夫々の能力が組合わさり、夫々の効果と共に相乗
効果を挙げ、極めて優れた皮膚用クリームを提供するこ
とが出来る。Effects of the Invention According to the present invention as described above, 0.05 to 0.5% of a licorice extract containing glucyrrhizinic acid as a main component,
1-10% Scutellaria extract, 1-1% Scutellaria extract
A medicated cream containing 0% Clara extract and 1 to 10% Clara extract is mixed and dissolved by heating the base squalane, petrolatum, and liquid paraffin, and then emulsified by adding hot purified water containing a preservative. , to which licorice extract and scutellariae extract,
After adding Scutellaria scutellariae extract and Clara extract, the product is manufactured by cooling while stirring, so that the anti-inflammatory effect of licorice extract, the anti-inflammatory effect as a flavonoid of Scutellaria extract, the anti-allergic effect, and the atopic type. Reaction suppressing effect, wound healing promoting effect based on the astringent anti-inflammatory effect of berberine, alkaloids, etc. of Auronicum extract, anti-inflammatory effect, ulcer prevention ability of matrine, the main alkaloid of Clara extract, skin By combining their respective abilities, such as the ability to deal with infectious diseases, we can create a synergistic effect with the effects of each, and provide an extremely excellent skin cream.
Claims (4)
出体を0.05〜1.0%、オウゴン抽出液を0.1〜
5%を含有させることを特徴とする薬用クリーム。Claim 1: 0.05 to 1.0% of a licorice extract mainly composed of glutyrrhizic acid, and 0.1 to 1.0% of a scutellariae extract.
A medicated cream characterized by containing 5%.
有させることを特徴とする請求項1に記載の薬用クリー
ム。2. The medicated cream according to claim 1, characterized in that it contains 0.1 to 10% of the extract of Aspergillus orientalis.
抽出液を0.1〜10%を含有させることを特徴とする
請求項1に記載の薬用クリーム。3. The medicated cream according to claim 1, characterized in that it contains 1 to 10% of the extract of Aspergillus oleracea and 0.1 to 10% of the extract of Clara.
ラフィンを加熱して混和溶解し、これに防腐剤を含む熱
精製水を加えて乳化し、これに甘草抽出体及びオウゴン
抽出液を加えた後、撹拌しながら冷却させることを特徴
とする薬用クリームの製造方法。4. The base materials squalane, petrolatum, and liquid paraffin are mixed and dissolved by heating, heat-purified water containing a preservative is added to emulsify the mixture, and licorice extract and scutellariae extract are added thereto. A method for producing a medicated cream, which comprises cooling while stirring.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3151176A JP2609562B2 (en) | 1991-05-27 | 1991-05-27 | Cream for allergic dermatitis and method for producing the same |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP3151176A JP2609562B2 (en) | 1991-05-27 | 1991-05-27 | Cream for allergic dermatitis and method for producing the same |
Publications (2)
Publication Number | Publication Date |
---|---|
JPH04346917A true JPH04346917A (en) | 1992-12-02 |
JP2609562B2 JP2609562B2 (en) | 1997-05-14 |
Family
ID=15512968
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP3151176A Expired - Fee Related JP2609562B2 (en) | 1991-05-27 | 1991-05-27 | Cream for allergic dermatitis and method for producing the same |
Country Status (1)
Country | Link |
---|---|
JP (1) | JP2609562B2 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04356424A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
JPH04356423A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
JPH09169637A (en) * | 1995-10-18 | 1997-06-30 | Sekisui Chem Co Ltd | External preparation for treating dermatosis |
EP0766960A4 (en) * | 1995-04-21 | 2000-07-12 | Seikisui Chemical Co Ltd | External preparations for treating dermatoses |
JP2001064192A (en) * | 1999-08-25 | 2001-03-13 | Sunstar Inc | Migration inhibitor for langerhans cell and antigen presentation inhibitor |
JP2009114146A (en) * | 2007-11-08 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | Transglutaminase-1 production promoter and involucrin production promoter |
JP2010519292A (en) * | 2007-02-21 | 2010-06-03 | バイオスペクトラム アイエヌシー | Composition for improving skin condition comprising matrine or oxymatrine |
CN112843113A (en) * | 2021-03-23 | 2021-05-28 | 南京医科大学 | A preparation for treating contact dermatitis |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8986748B2 (en) * | 2008-12-23 | 2015-03-24 | The Dial Corporation | Combinations of herb extracts having synergistic antioxidant effect, and methods relating thereto |
KR102417303B1 (en) | 2017-11-24 | 2022-07-06 | (주)아모레퍼시픽 | Composition for preventing or improving atopic dermatitis |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53136509A (en) * | 1977-05-04 | 1978-11-29 | Akira Hamaguchi | Production of dermatophytosis treating agent |
JPS62292725A (en) * | 1986-06-12 | 1987-12-19 | Nitto Electric Ind Co Ltd | Remedy for insect bite |
JPH01305034A (en) * | 1988-06-01 | 1989-12-08 | Teika Corp | Production of 'ougon' extract and cosmetic containing the same |
JPH0236113A (en) * | 1988-07-26 | 1990-02-06 | Ichimaru Pharcos Co Ltd | External use of scutellariae radix powder |
-
1991
- 1991-05-27 JP JP3151176A patent/JP2609562B2/en not_active Expired - Fee Related
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS53136509A (en) * | 1977-05-04 | 1978-11-29 | Akira Hamaguchi | Production of dermatophytosis treating agent |
JPS62292725A (en) * | 1986-06-12 | 1987-12-19 | Nitto Electric Ind Co Ltd | Remedy for insect bite |
JPH01305034A (en) * | 1988-06-01 | 1989-12-08 | Teika Corp | Production of 'ougon' extract and cosmetic containing the same |
JPH0236113A (en) * | 1988-07-26 | 1990-02-06 | Ichimaru Pharcos Co Ltd | External use of scutellariae radix powder |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH04356424A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
JPH04356423A (en) * | 1991-05-31 | 1992-12-10 | Masao Saito | Medicated cream and its production |
EP0766960A4 (en) * | 1995-04-21 | 2000-07-12 | Seikisui Chemical Co Ltd | External preparations for treating dermatoses |
US6248779B1 (en) | 1995-04-21 | 2001-06-19 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
EP1374861A1 (en) * | 1995-04-21 | 2004-01-02 | Sekisui Kagaku Kogyo Kabushiki Kaisha | External preparations for treating dermatoses |
JPH09169637A (en) * | 1995-10-18 | 1997-06-30 | Sekisui Chem Co Ltd | External preparation for treating dermatosis |
JP2001064192A (en) * | 1999-08-25 | 2001-03-13 | Sunstar Inc | Migration inhibitor for langerhans cell and antigen presentation inhibitor |
JP2010519292A (en) * | 2007-02-21 | 2010-06-03 | バイオスペクトラム アイエヌシー | Composition for improving skin condition comprising matrine or oxymatrine |
JP2009114146A (en) * | 2007-11-08 | 2009-05-28 | Maruzen Pharmaceut Co Ltd | Transglutaminase-1 production promoter and involucrin production promoter |
CN112843113A (en) * | 2021-03-23 | 2021-05-28 | 南京医科大学 | A preparation for treating contact dermatitis |
CN112843113B (en) * | 2021-03-23 | 2022-02-01 | 南京医科大学 | A preparation for treating contact dermatitis |
Also Published As
Publication number | Publication date |
---|---|
JP2609562B2 (en) | 1997-05-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101239879B1 (en) | Cosmetic composition for mitigating skin troubles | |
KR101337415B1 (en) | Clude drug composition for treatment atopy and acne | |
JPH04356424A (en) | Medicated cream and its production | |
CN111870568B (en) | Anti-allergy itching-relieving plant composition and preparation method and application thereof | |
JP2003089658A (en) | Skin lotion and food excellent in anti-itchiness effectiveness | |
JPH04346917A (en) | Medicated cream and production thereof | |
WO2003099200A2 (en) | Composition and method for the treatment of diaper rash using natural products | |
KR20190068361A (en) | Composition comprising Plant Extract Complex for Anti-bacteria, Anti-inflammation, Anti-oxidation, Inhibiting Sebum Secretion and Improving Dermatitis | |
US10780141B2 (en) | Herbal combinations for treating eczema | |
CN109620879A (en) | A kind of wet repairing paste and preparation method thereof clearly | |
CN109431943A (en) | It is a kind of for the maintenance cream of infant eczema and its preparation | |
WO2006007680A1 (en) | Pharmaceutical compositions from carapa guianensis | |
JP2609563B2 (en) | Cream for allergic dermatitis and method for producing the same | |
JPH01172331A (en) | Preventive and remedy for infectious diseases of pasteurella haemolytica of mammals | |
US20170049835A1 (en) | Herbal Combinations For Treating Scalp Conditions | |
JPH10218784A (en) | Medicine for external use for treating allergic dermatitis | |
US20160375076A1 (en) | Herbal Combinations for Treating Eczema | |
Semkina | Ointments, gels, liniments, and creams containing phytopreparations (a review) | |
JPH0482835A (en) | Remedy for dyspigmentation | |
KR20110079088A (en) | Cosmetic composition containing purified catechin for atopic dermatitis | |
CN111358851A (en) | Gel for treating pet skin diseases and preparation method thereof | |
JP2001131079A (en) | Skin preparation for external use | |
CN110812377A (en) | Acne treatment and repair composition and application thereof | |
CN109568519A (en) | A kind of Chinese medicine composition and preparation method thereof for eczema | |
JP2004352680A (en) | Composition for treatment of allergic disease |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 19961022 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20090213 Year of fee payment: 12 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20100213 Year of fee payment: 13 |
|
FPAY | Renewal fee payment (event date is renewal date of database) |
Free format text: PAYMENT UNTIL: 20110213 Year of fee payment: 14 |
|
LAPS | Cancellation because of no payment of annual fees |